Endovasc Presents Liprostin Results in Elderly Diabetics at Rome Conference on November 26th; Giovanni Brotzu MD will Review Treatment of Critical Ischemia and Polyneuropathy.

Business Editors/Health/Medical Writers

Italian Society of Artero-Venous Pathology

MONTGOMERY, Texas--(BUSINESS WIRE)--Oct. 2, 2003

Endovasc, Inc (EVSC OTC BB) announced today that it would present the results of Liprostin(TM) treatments in elderly critical limb ischemia patients at the conference of the Italian Society of Artero-Venous Pathology in Rome, Italy. Professor Giovanni Brotzu, MD, will present the results of 18 patients treated over a three month period.

Professor Giovanni Brotzu, MD, is Chair of Vascular surgery, Department of Surgical Sciences and Organ Transplantation at University of Cagliari, Calgary Italy. The average age of the patient-enrollee was 75 years of age, the youngest being 51, and the two oldest being 90 years of age. All except one patient (classed IIb) suffered from severe limb disease of either stage III or IV (Fountaine) with stage V considered the most severe. Two patients had Buerger's disease and 3 had chronic renal deficiency and were undergoing dialysis treatment. Walking distances at the beginning of the trial were limited to 1130 meters or an average of 63 meters per patient.

Results for the group at the conclusion of the study were significant. Walking distance at the end of the 3-month trial improved by a mean of 54% or an average of 97 meters per patient. The most dramatic increase came in the first month with a remarkable gain of 76% or average 111 meters per patent. Equally remarkable, 13 ulcerated skin lesions were observed upon commencement of the trial covering an aggregated length total of 72.5 centimeters of ulcerated lesion. At the end of the 3-month trial, only 7 lesions remained visible. Of the remaining lesions the mean length was reduced to 27.2 centimeters, approximating a healing response of 62%.

"Our preliminary experience with Liprostin(TM) demonstrated that the drug is extremely efficacious," said Dr. Giovanni Brotzu. "The results of the study clearly demonstrate a reduction and/or elimination of rest pain, walking pain, and increase in walking distance. With major improvement of atrophic lesions, it leads to a remarkable improvement in the patient's quality of life. I look forward towards sharing my findings with the scientific community in more detail."

Endovasc Chairman and CEO, Dr. David Summers said, "We are especially pleased at the remarkable testing results of Liprostin in diabetic patients. There minimal treatment options for diabetic patients at the stage of the disease that Dr. Brotzu treated them. His success with this polytrophic drug encourages us to continue our testing to get Liprostin approved worldwide as soon as possible."

About Endovasc

Endovasc, Inc., established in 1996, is an early-stage drug development company that pioneers new cardiovascular and metabolic drug therapies that are designed to deliver and release drugs to their intended targets in an efficient and controlled manner. Endovasc's lead drug candidates include Angiogenix(TM), Liprostin(TM), PROStent(TM) stent-coating technology, biodegradable stents and other drug-delivery stents.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc, please visit www.endovasc.com.